Tandem Diabetes Care (TNDM) Shareholder's Equity Growth (1y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.74% |
| Dec 31, 2025 | -41.02% |
| Sep 30, 2025 | -44.06% |
| Jun 30, 2025 | -43.01% |
| Mar 31, 2025 | -36.11% |
| Dec 31, 2024 | -16.11% |
| Sep 30, 2024 | -24.30% |
| Jun 30, 2024 | -28.96% |
| Mar 31, 2024 | -28.25% |
| Dec 31, 2023 | -28.71% |
| Sep 30, 2023 | -25.56% |
| Jun 30, 2023 | -26.77% |
| Mar 31, 2023 | -22.55% |
| Dec 31, 2022 | 1.58% |
| Sep 30, 2022 | 8.26% |
| Jun 30, 2022 | 29.91% |
| Mar 31, 2022 | 39.55% |
| Dec 31, 2021 | 18.24% |
| Sep 30, 2021 | 19.33% |
| Jun 30, 2021 | 29.28% |
| Mar 31, 2021 | 51.28% |
| Dec 31, 2020 | 87.87% |
| Sep 30, 2020 | 95.54% |
| Jun 30, 2020 | 84.19% |
| Mar 31, 2020 | 71.27% |
| Dec 31, 2019 | 48.53% |
| Sep 30, 2019 | 44.67% |
| Jun 30, 2019 | 458.93% |
| Mar 31, 2019 | 921.03% |
| Dec 31, 2018 | 550.37% |
| Sep 30, 2018 | 512.87% |
| Jun 30, 2018 | 242.26% |
| Mar 31, 2018 | 734.21% |
| Dec 31, 2017 | -391.78% |
| Sep 30, 2017 | -637.96% |
| Jun 30, 2017 | -156.99% |
| Mar 31, 2017 | -104.07% |
| Dec 31, 2016 | -109.34% |
| Sep 30, 2016 | -92.70% |
| Jun 30, 2016 | -63.45% |
| Mar 31, 2016 | -55.07% |
| Dec 31, 2015 | 16.30% |
| Sep 30, 2015 | 5.56% |
| Jun 30, 2015 | 5.03% |
| Mar 31, 2015 | 5.13% |
| Dec 31, 2014 | -52.77% |